TickerFacts.

Endonovo Therapeutics, Inc. (ENDV): Capital Expenditures

Annual figures by period end, from SEC filings.

Not updated since 2022-12-31. No annual report in US GAAP has been filed since. Companies that switch to IFRS reporting, as many foreign filers do, or stop filing are not updated here.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2015-12-31 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

Older than the company's other figures. The latest Capital Expenditures is for the year ended 2019-12-31, while the company's latest annual report covers the year ended 2022-12-31. Its later filings do not report this line under the concept TickerFacts maps.

$2.6K
Year ended 2019-12-31
$9.0K2014-12-31: $02015-12-31: $3.8K2018-12-31: $9.0K2019-12-31: $2.6K$2.6K
2014-12-31 Capital Expenditures (USD) 2019-12-31
Period endedCapital ExpendituresChange YoYSource filing
2019-12-31$2.6K-71.1%2021-04-13, From 2019-01-01
2018-12-31$9.0Kn/a2020-05-04, From 2018-01-01
No annual figure between 2015-12-31 and 2018-12-31.
2015-12-31$3.8Kn/c2017-04-17, From 2015-01-01
2014-12-31$0n/a2016-05-17, From 2014-01-01